<DOC>
	<DOC>NCT03014102</DOC>
	<brief_summary>The purpose of this study is to determine whether recombinant human thrombopoietin are effective in peripheral blood progenitor cells mobilization for autologous transplantation.</brief_summary>
	<brief_title>Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation</brief_title>
	<detailed_description />
	<criteria>a histologically confirmed diagnosis of Hodgkin's disease, nonHodgkin's lymphoma, or selected highrisk solid tumors that are planned to receive autologous peripheral blood progenitor cell transplantation Eastern Cooperative Oncology Group performance status of 0 2. abnormal liver function (aminotransferase or bilirubin levels 2 times upper limit of normal), leukopenia (white blood cell count 3000/L), or a history of platelet or other disorders associated with a bleeding diathesis a history of thromboembolic disease, coronary heart disease,stroke, arrhythmias, central nervous system metastases,or other organ system diseases or abnormalities that might predispose individuals to treatmentrelated complications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>